去甲西泮 - CAS号 1088-11-5

物化性质

稳定性/保质期：
1. 可燃，在火场中会分解出有毒的氯化氢和氮氧化物气体。

计算性质

辛醇/水分配系数(LogP)：

2.9
重原子数：

19
可旋转键数：

1
环数：

3.0
sp3杂化的碳原子比例：

0.066
拓扑面积：

41.5
氢给体数：

1
氢受体数：

2

ADMET

代谢

Nordiazepam已知的人类代谢物包括Oxazepam。

Nordiazepam has known human metabolites that include Oxazepam.

来源:NORMAN Suspect List Exchange

毒理性

毒性总结

苯二氮卓类药物非特异性地与苯二氮卓受体BNZ1结合，介导睡眠，以及与BNZ2结合，影响肌肉松弛、抗惊厥活性、运动协调和记忆。由于认为苯二氮卓受体与γ-氨基丁酸-A（GABAA）受体相偶联，这通过增加GABA对GABA受体的亲和力来增强GABA的效果。抑制性神经递质GABA与该位点的结合打开了氯通道，导致细胞膜超极化，防止细胞进一步兴奋。

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

来源:Toxin and Toxin Target Database (T3DB)

毒理性

致癌物分类

对人类无致癌性（未列入国际癌症研究机构IARC清单）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

暴露处理

一般支持性措施应予以实施，包括静脉输液，并保持气道通畅。低血压可以通过使用norepinephrine（去甲肾上腺素）或metaraminol（甲拉明）来对抗。透析的价值有限。Flumazenil（安易醒）是一种竞争性的苯二氮卓受体拮抗剂，可以用作苯二氮卓类药物过量的解毒剂。特别是，flumazenil非常有效地逆转与苯二氮卓类药物相关的中枢神经系统抑制，但对逆转呼吸抑制的效果较差。然而，其使用存在争议，因为它有许多禁忌症。长期服用苯二氮卓类药物的患者、服用降低癫痫发作阈值的物质的患者，或心动过速或有癫痫病史的患者禁用。一般来说，医疗观察和支持性护理是治疗苯二氮卓类药物过量的主要手段。尽管苯二氮卓类药物可以被活性炭吸收，但在纯苯二氮卓类药物过量中，使用活性炭进行胃部净化并无益处，因为不良反应的风险通常超过该程序可能带来的任何潜在益处。只有在苯二氮卓类药物与其他可能从净化中受益的药物联合服用时，才建议使用。胃灌洗（胃抽吸）或全肠灌洗也不推荐使用。

General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

来源:Toxin and Toxin Target Database (T3DB)

制备方法与用途

制备方法

用5-氯-2-(氯乙酰氨基)二苯酮与六亚甲基四胺在碱性条件下反应制得。

合成制备方法

用5-氯-2-(氯乙酰氨基)二苯酮与六亚甲基四胺在碱性条件下反应制得。

上下游信息

上游原料

中文名称	英文名称	CAS号	化学式	分子量
地西泮	diazepam	439-14-5	C₁₆H₁₃ClN₂O	284.745
地莫西泮	7-chloro-4-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-one	963-39-3	C₁₅H₁₁ClN₂O₂	286.718
氯卓酸	clorazepate	23887-31-2	C₁₆H₁₁ClN₂O₃	314.728
——	5-(4-methoxyphenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one	137404-89-8	C₁₆H₁₄N₂O₂	266.299
普拉西	prazepam	2955-38-6	C₁₉H₁₇ClN₂O	324.81
硝西泮	nitrazepam	146-22-5	C₁₅H₁₁N₃O₃	281.271
——	7-chlor-1-methyl-2-chloromethyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin	54960-29-1	C₁₇H₁₆Cl₂N₂	319.233
硝甲西泮	nimetazepam	2011-67-8	C₁₆H₁₃N₃O₃	295.298
N-去甲基-N(4)-去氧利眠宁	2-amino-7-chloro-5-phenyl-3H-1,4-benzodiazepine	7564-07-0	C₁₅H₁₂ClN₃	269.733
2-溴乙酰胺-5-氯苯甲酮	N-(2-benzoyl-4-chlorophenyl)-2-bromoacetamide	32580-26-0	C₁₅H₁₁BrClNO₂	352.615
7-氯-1,3,4,5-四氢-5-苯基-2H-1,4-苯并二氮杂卓-2-酮	7-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-one	1824-69-7	C₁₅H₁₃ClN₂O	272.734
2-苯甲酰-2,4-二氯乙酰苯胺	5-chloro-2-(chloroacetylamino)benzophenone	4016-85-7	C₁₅H₁₁Cl₂NO₂	308.164
——	7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine	112393-62-1	C₁₅H₁₃ClN₄	284.748

1
2

下游产品

中文名称	英文名称	CAS号	化学式	分子量
7-氯-1,3-二氢-5-(4-羟基苯基)-2H-1,4-苯并二氮杂卓-2-酮	4'-hydroxy-N-desmethyldiazepam	17270-12-1	C₁₅H₁₁ClN₂O₂	286.718
7-氯-2,3-二氢-5-苯基-1H-1,4-苯并二氮杂卓	7-chloro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine	1694-78-6	C₁₅H₁₃ClN₂	256.735
地西泮	diazepam	439-14-5	C₁₆H₁₃ClN₂O	284.745
——	7-chloro-1,3-dihydro-1-[11C]methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	——	C₁₆H₁₃ClN₂O	283.734
舒宁	oxazepam	604-75-1	C₁₅H₁₁ClN₂O₂	286.718
N-乙基去甲西泮	7-chloro-5-phenyl-1,3-dihydro-1-ethyl-2H-1,4-benzodiazepin-2-one	5571-65-3	C₁₇H₁₅ClN₂O	298.772
——	Nordiazepam, N-propyl-	——	C₁₈H₁₇ClN₂O	312.8
——	1-acetyl-7-chloro-5-phenyl-1H-benzo[e][1,4]-diazepin-2(3H)-one	27046-54-4	C₁₇H₁₃ClN₂O₂	312.755
匹那西泮	pinazepam	52463-83-9	C₁₈H₁₃ClN₂O	308.767
7-氯-1,3-二甲基-5-苯基-1,3-二氢-2H-1,4-苯并二氮杂-2-酮	7-Chloro-1,3-dimethyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one	50882-52-5	C₁₇H₁₅ClN₂O	298.772
——	1,2-Dihydro-1-isopropyl-2-oxo-5-phenyl-7-chlor-3H-1,4-benzodiazepin	17615-40-6	C₁₈H₁₇ClN₂O	312.799
——	7-chloro-1-(2-methanesulfinyl-ethyl)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one	33691-00-8	C₁₈H₁₇ClN₂O₂S	360.864
——	(7-chloro-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-2-yl)-methyl-amine	——	C₁₆H₁₆ClN₃	285.776
3-乙酰氧基-7-氯-1,3-二氢-5-苯基-2H-1,4-苯并二氮杂革-2-酮	oxazepam 3-acetate	1824-74-4	C₁₇H₁₃ClN₂O₃	328.755
——	(7-chloro-2-oxo-5-phenyl-2,3-dihydro-benzo[e][1,4]diazepin-1-yl)-acetic acid	27016-88-2	C₁₇H₁₃ClN₂O₃	328.755
——	1-(3'-carboxylpropyl)-7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one	64581-01-7	C₁₉H₁₇ClN₂O₃	356.809
7-氯-2,3-二氢-2-氧代-5-苯基-1H-1,4-苯并二氮杂卓-3-羧酸乙酯	7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid ethyl ester	5606-55-3	C₁₈H₁₅ClN₂O₃	342.782
——	7-chloro-1-(2,2-dimethoxy-ethyl)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one	65868-11-3	C₁₉H₁₉ClN₂O₃	358.824
——	7-chloro-5-phenyl-1-<3-(4-phenylpiperazino)propyl>-1,3-dihydro-1,4-benzodiazepin-2-one	90503-69-8	C₂₈H₂₉ClN₄O	473.017
——	1-(3'-carbomethoxypropyl)-7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one	189744-30-7	C₂₀H₁₉ClN₂O₃	370.835
——	(7-chloro-2-oxo-5-phenyl-2,3-dihydro-benzo[e][1,4]diazepin-1-yl)-acetic acid methyl ester	2511-40-2	C₁₈H₁₅ClN₂O₃	342.782
——	1-benzyl-7-chloro-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one	5627-87-2	C₂₂H₁₇ClN₂O	360.843
——	(7-chloro-2-oxo-5-phenyl-2,3-dihydro-benzo[e][1,4]diazepin-1-yl)-acetic acid ethyl ester	2511-38-8	C₁₉H₁₇ClN₂O₃	356.809
——	7-chloro-1,3-dihydro-5-phenyl-1-{3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl}-2H-1,4-benzodiazepin-2-one	——	C₂₃H₂₅ClN₂O₃	412.916
——	tert-butyl 2-(7-chloro-2-oxo-5-phenyl-3H-1,4-benzodiazepin-1-yl)acetate	217189-27-0	C₂₁H₂₁ClN₂O₃	384.862
——	7-chloro-1-[3-(2-methyl-[1,3]dioxolan-2-yl)-propyl]-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one	65458-62-0	C₂₂H₂₃ClN₂O₃	398.889
——	1-methyl-3-(dimethylaminomethylene)-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one	——	C₁₉H₁₈ClN₃O	339.824
——	7-chloro-5-phenyl-3-thiophen-2-ylmethylene-1,3-dihydro-benzo[e][1,4]diazepin-2-one	55056-39-8	C₂₀H₁₃ClN₂OS	364.855
——	7-chloro-1-[(4-methoxyphenyl)methyl]-5-phenyl-3H-1,4-benzodiazepin-2-one	497875-19-1	C₂₃H₁₉ClN₂O₂	390.869
——	3-benzyl-7-chloro-1-methyl-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one	29580-36-7	C₂₃H₁₉ClN₂O	374.87
——	(3RS)-7-chloro-1,3-dihydro-3-[(1SR)-1-hydroxypropyl]-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	——	C₁₉H₁₉ClN₂O₂	342.825
——	7-chloro-1,3-dihydro-1-diphenylmethyl-5-phenyl-2H-1,4-benzodiazepin-2-one	——	C₂₈H₂₁ClN₂O	436.941
——	(3RS)-7-chloro-1,3-dihydro-3-[(1RS)-1-hydroxybutyl]-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	——	C₂₀H₂₁ClN₂O₂	356.852
——	(3RS)-7-chloro-1,3-dihydro-3-[(1SR)-1-hydroxy-3-methylbutyl]-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	——	C₂₁H₂₃ClN₂O₂	370.879
——	7-chloro-2,3-dihydro-α,α-dimethyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-acetic acid methyl ester	——	C₂₀H₁₉ClN₂O₃	370.835
——	7-Chloro-1,3-dihydro-1-(2,2-dimethoxyethyl)-5-phenyl-2H-1,4-benzodiazepine-2-thione	——	C₁₉H₁₉ClN₂O₂S	374.891
——	7-chloro-1,3-dihydro-2-(dimethoxymalonylidene)-5-phenyl-2H-1,4-benzodiazepine	53216-88-9	C₂₀H₁₇ClN₂O₄	384.819
——	(3RS)-7-chloro-3-[(1RS)-(4-chlorophenyl)hydroxymethyl]-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	——	C₂₃H₁₈Cl₂N₂O₂	425.314
——	1-[4-butanoyl-(p-bis(2-chloroethyl)amino)-L-phenylalanine ethyl ester]-7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one	——	C₃₄H₃₇Cl₃N₄O₄	672.051
——	7-chloro-1-(2,5-dimethoxyphenacyl)-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one	77778-69-9	C₂₅H₂₁ClN₂O₄	448.906
——	(3RS)-7-chloro-1,3-dihydro-3-[(1SR)-hydroxy(4-methoxyphenyl)methyl]-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	——	C₂₄H₂₁ClN₂O₃	420.895
——	(3RS)-7-chloro-1,3-dihydro-3-[(1SR)-hydroxy(4-nitrophenyl)methyl]-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	——	C₂₃H₁₈ClN₃O₄	435.867
——	7-chloro-α,α-dimethyl-2,3-dihydro-2-thioxo-5-phenyl-1H-1,4-benzodiazepin-1-acetic acid methyl ester	——	C₂₀H₁₉ClN₂O₂S	386.902
1,3-二氢-5-苯基-7-氯-2H-1,4-苯并二氮杂卓-2-硫酮	7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-thione	4547-02-8	C₁₅H₁₁ClN₂S	286.785
7-氯-1,3,4,5-四氢-5-苯基-2H-1,4-苯并二氮杂卓-2-酮	7-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-one	1824-69-7	C₁₅H₁₃ClN₂O	272.734
N(4)-去氧利眠宁	2-(methylamino)-5-phenyl-7-chloro-3H-1,4-benzodiazepine	4393-72-0	C₁₆H₁₄ClN₃	283.76
——	(7-chloro-5-phenyl-3H-benzo[e][1,4]diazepin-2-yl)-dimethyl-amine	23895-04-7	C₁₇H₁₆ClN₃	297.787
——	7-chloro-2-(N-nitrosomethylamino)-5-phenyl-3H-1,4-benzodiazepine	819793-73-2	C₁₆H₁₃ClN₄O	312.758
——	2-(2-dimethylaminoethylthio)-5-phenyl-7-chloro-3H-1,4-benzodiazepine	67974-46-3	C₁₉H₂₀ClN₃S	357.907

1
2
3
4
5

反应信息

作为反应物：

描述：

去甲西泮在溶剂黄146 作用下，以甲醇为溶剂，反应 120.0h，以55%的产率得到7-氯-1,3,4,5-四氢-5-苯基-2H-1,4-苯并二氮杂卓-2-酮

参考文献：

名称：

COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION

摘要：

本发明的主题是新型化合物家族，其中包括芳香胺、亚胺、氨基金刚烷和苯二氮卓衍生物，包括相同的药物和将其用作抑制具有细胞内活性的毒素（例如蓖麻毒素）以及利用内化途径感染细胞的病毒的药物。

公开号：

US20160083355A1
作为产物：

描述：

N,N'-methylenebis<3-(2-benzoyl-4'-chloro)phenyl>-4-imidazolidinone 在 ammonium hydroxide 作用下，以乙醇为溶剂，以100%的产率得到去甲西泮

参考文献：

名称：

咪唑啉丁-4-酮的合成及其转化为1,4-苯并二氮杂-2-酮

摘要：

α-卤代乙酰苯胺Ia-e与乙醇中的六胺反应，生成双咪唑啉丁-4-酮衍生物IIa-e，该衍生物在酸性介质中水解成相应的单咪唑啉丁-4-酮Ⅲa-e。在不同条件下，在多种试剂的存在下，化合物IIa-d被转化为1,4-苯并二氮杂-2-酮。产率在50％至100％之间。

DOI：

10.1002/jhet.5570180523
作为试剂：

描述：

1-Boc-4-甲基-4-哌啶甲酸、三乙胺、二苯基膦叠氮化物、苯甲醇在乙酸乙酯、氯化铵、氯化钠、 Sodium sulfate-III 作用下，以去甲西泮、甲苯为溶剂，反应 16.75h，以to provide the desired product as a semi-solid (25 g), which的产率得到4-苄氧基羰氨基-1-N-丁氧基羰基-4-甲基哌啶

参考文献：

名称：

IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS

摘要：

化学式（I）的化合物是受体酪氨酸激酶抑制剂，可用于治疗由类（3）和类（5）受体酪氨酸激酶介导的疾病。该发明的特定化合物也被发现是Pim-1的抑制剂。

公开号：

US20100144751A1

点击查看最新优质反应信息

文献信息

New and mild method for the synthesis of alprazolam and diazepam and computational study of their binding mode to GABAA receptor

作者：Ahmad R. Massah、Sajjad Gharaghani、Hamid Ardeshiri Lordejani、Nahad Asakere

DOI：10.1007/s00044-016-1585-z

日期：2016.8

A new method for the synthesis of 8-chloro-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (alprazolam) and 7-chloro-1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (diazepam) from 2-amino-5-chloro benzophenone was described under mild conditions. Most of the synthetic steps were carried out under solvent-free conditions, and the products were obtained in high yield and purity

合成8-氯-1-甲基-6-苯基-4H-苯并[f] [1,2,4]三唑[4,3-a] [1,4]二氮杂（阿普唑仑）的新方法和描述了在温和条件下由2-氨基-5-氯二苯甲酮生成的7-氯-1-甲基-5-苯基-1H-苯并[e] [1,4]二氮杂-2-2（3H）-一（地西p）。大部分合成步骤均在无溶剂条件下进行，并以高收率和高纯度获得了产物。通过与真实样品的物理性质比较以及IR，1 H NMR和13 C NMR来表征产物。三维（3D）GABA的模型甲使用的X射线晶体结构，构建homopentameric线虫谷氨酸-门控氯离子通道（GluCl）基于序列比较和同源性建模方法，以3.3Å（3RHW）为模板。同源性建模和MD模拟研究预测了水环境中受体的3D结构。所得的受体构象用于阿普唑仑和地西epa的对接。对接研究表明药物与受体有许多重要的相互作用。此外，将GABA与药物的复合物用于MD模拟，以实现复合物的构象变化。
[EN] TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS<br/>[FR] TRAITEMENT DE TROUBLES DU SPECTRE AUTISTIQUE, DE TROUBLES OBSESSIVO-COMPULSIFS ET DE TROUBLES DE L'ANXIÉTÉ

申请人：RUGEN HOLDINGS CAYMAN LTD

公开号：WO2018098128A1

公开（公告）日：2018-05-31

Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.

揭示了通过给予特定NR2B亚单位选择性NMDA（N-甲基-D-天冬氨酸）拮抗剂来治疗NMDA受体介导的疾病的方法。NMDA受体介导的疾病包括自闭症谱系障碍、强迫症和焦虑症。
[EN] TREATMENT OF ANXIETY DISORDERS AND AUTISM SPECTRUM DISORDERS<br/>[FR] TRAITEMENT DES TROUBLES DE L'ANXIÉTÉ ET DES TROUBLES DU SPECTRE AUTISTIQUE

申请人：RUGEN HOLDINGS CAYMAN LTD

公开号：WO2016049048A1

公开（公告）日：2016-03-31

Disclosed are methods for treating autism spectrum disorders and/or anxiety disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. Anxiety disorders include agoraphobia (with or without panic disorder), generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder (PD), post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD).

本文披露了通过给予特定NR2B亚单位选择性NMDA（N-甲基-D-天冬氨酸）拮抗剂来治疗自闭症谱系障碍和/或焦虑障碍的方法。焦虑障碍包括广场恐惧症（伴有或不伴有惊恐障碍）、广泛性焦虑障碍（GAD）、社交焦虑障碍（SAD）、惊恐障碍（PD）、创伤后应激障碍（PT SD）和强迫症（OCD）。
Compounds and compositions for use in the prevention and treatment of obesity and related syndromes

申请人：Chapal Nicolas

公开号：US20060223884A1

公开（公告）日：2006-10-05

The invention relates to 4-hydroxyisoleucine, isomers, analogs, lactones, salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. More particularly, the invention relates to the use of those compounds in the prevention and treatment of obesity and related syndromes.

本发明涉及4-羟基异亮氨酸、其同分异构体、类似物、内酯、盐和前药，以及它们的制备过程，以及包含它们的药物组合物。更具体地说，本发明涉及这些化合物在预防和治疗肥胖及相关综合症中的用途。
[EN] SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE L'ONCOPROTÉINE MCL-1 ET LEURS UTILISATIONS

申请人：UNIV MARYLAND

公开号：WO2017011323A1

公开（公告）日：2017-01-19

Compounds that inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.

提供抑制髓样细胞白血病-1（Mcl-1）癌蛋白的化合物，以及使用相同化合物治疗疾病的方法。

表征谱图

氢谱

1HNMR
质谱

MS
碳谱

13CNMR
红外

IR
拉曼

Raman

查看更多图谱数据，请前往“摩熵化学”平台

峰位数据
峰位匹配
表征信息

Shift(ppm)

Intensity

查看更多图谱数据，请前往“摩熵化学”平台

Assign

Shift(ppm)

查看更多图谱数据，请前往“摩熵化学”平台

测试频率

样品用量

溶剂

溶剂用量

查看更多图谱数据，请前往“摩熵化学”平台

去甲西泮 | 1088-11-5

分子结构分类

物化性质

计算性质

ADMET

制备方法与用途

上下游信息

反应信息

文献信息

表征谱图

同类化合物

相关结构分类

热门分子